Edition:
United States

Zafgen Inc (ZFGN.OQ)

ZFGN.OQ on NASDAQ Stock Exchange Global Select Market

7.09USD
22 Jun 2018
Change (% chg)

$0.38 (+5.66%)
Prev Close
$6.71
Open
$6.75
Day's High
$7.09
Day's Low
$6.44
Volume
2,042,592
Avg. Vol
56,636
52-wk High
$10.00
52-wk Low
$3.21

Chart for

About

Zafgen, Inc. is a biopharmaceutical company. The Company is focused on improving the health and well-being of patients affected by obesity and complex metabolic disorders. The Company's lead product candidate, Beloranib, is a twice-weekly subcutaneous injection being developed for the treatment of multiple indications, including... (more)

Overall

Beta: -0.56
Market Cap(Mil.): $195.42
Shares Outstanding(Mil.): 27.56
Dividend: --
Yield (%): --

Financials

  ZFGN.OQ Industry Sector
P/E (TTM): -- 248.83 34.14
EPS (TTM): -2.00 -- --
ROI: -56.11 -5.25 13.10
ROE: -62.55 -6.83 15.09

BRIEF-Zafgen Reports Q1 Loss Per Share $0.58

* ZAFGEN REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

May 08 2018

BRIEF-Zafgen Reports Q4 Loss Per Share $0.48

* ZAFGEN REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS; ANNOUNCES POSITIVE INTERIM DATA FROM ONGOING ZGN-1061 PHASE 2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH TYPE 2 DIABETES

Mar 06 2018

BRIEF-Zafgen Says Co Entered Into Loan And Security Agreement Providing For Term Loan With Principal Amount​ Of $20 Mln

* ZAFGEN SAYS ‍ON DEC 29, CO ENTERED INTO LOAN AND SECURITY AGREEMENT PROVIDING FOR TERM LOAN WITH PRINCIPAL AMOUNT​ OF $20 MILLION - SEC FILING Source text: [http://bit.ly/2Earwn6] Further company coverage:

Jan 05 2018

BRIEF-Zafgen Reports Strong Clinical Progress And Updates Outlook For 2018

* ZAFGEN REPORTS STRONG CLINICAL PROGRESS AND UPDATES OUTLOOK FOR 2018

Jan 05 2018

Earnings vs. Estimates